|
Case mix, outcome and activity for major subgroups of dermatological admissions |
|||
| Infective conditions |
Dermatological malignancies |
Acute skin failure |
|
|
|
|||
| Admissions, n (% of all admissions) |
1,926 (0.40) |
191 (0.04) |
199 (0.04) |
|
|
|||
| Age, mean (SD) |
57.6 (16.5) |
65.1 (15.0) |
51.7 (20.8) |
|
|
|||
| Male, n (%) |
1,009 (52.4) |
112 (58.6) |
90 (45.2) |
|
|
|||
| Surgical status, n (%): |
|||
| Non-surgical |
1,016 (52.8) |
38 (19.9) |
170 (85.4) |
| Elective |
172 (8.9) |
138 (72.3) |
16 (8.0) |
| Emergency |
737 (38.3) |
15 (7.9) |
13 (6.5) |
|
|
|||
| Past medical history*, n (%): |
|||
| Steroid treatment |
65 (3.4) |
3 (1.6) |
12 (6.1) |
| Chemotherapy |
43 (2.3) |
8 (4.2) |
13 (6.6) |
| Metastatic disease |
17 (0.9) |
25 (13.2) |
0 (0.0) |
| Chronic renal replacement therapy |
37 (1.9) |
1 (0.5) |
5 (2.5) |
| Severe respiratory disease |
32 (1.7) |
1 (0.5) |
3 (1.5) |
| Very severe cardiovascular disease |
26 (1.4) |
3 (1.6) |
3 (1.5) |
| Radiotherapy |
15 (0.8) |
11 (5.8) |
1 (0.5) |
| Lymphoma |
19 (1.0) |
1 (0.5) |
6 (3.0) |
| Acute myelogenous/lymphocytic leukaemia or multiply myeloma |
11 (0.6) |
0 (0.0) |
3 (1.5) |
| Portal hypertension |
12 (0.6) |
0 (0.0) |
1 (0.5) |
| Biopsy proven cirrhosis |
12 (0.6) |
0 (0.0) |
0 (0.0) |
| Chronic myelogenous/lymphocytic leukaemia |
8 (0.4) |
1 (0.5) |
1 (0.5) |
| Home ventilation |
8 (0.4) |
1 (0.5) |
0 (0.0) |
| Congenital immunohumoral or cellular immune deficiency state |
5 (0.3) |
0 (0.0) |
1 (0.5) |
| Hepatic encephalopathy |
5 (0.3) |
0 (0.0) |
0 (0.0) |
| AIDS |
2 (0.1) |
0 (0.0) |
0 (0.0) |
|
|
|||
| APACHE II score, mean (SD) |
19.1 (7.5) |
14.5 (5.3) |
18.1 (7.0) |
|
|
|||
| ICNARC model: |
|||
| Physiology score, mean (SD) |
22.7 (10.4) |
12.1 (6.7) |
21.2 (10.6) |
| Predicted mortality, median (IQR) |
37.6 (16.7–64.5) |
10.1 (6.2–19.2) |
32.7 (12.3–62.7) |
|
|
|||
| ICU length of stay (days), median (IQR): |
|||
| ICU survivor |
4.1 (1.7–10.0) |
1.0 (0.8–2.0) |
4.7 (1.9–14.8) |
| ICU non-survivor |
1.9 (0.7–5.8) |
1.0 (0.3–4.0) |
4.7 (2.0–10.0) |
| Transfer to another ICU |
4.0 (0.9–9.6) |
- |
3.5 (0.7–11.6) |
|
|
|||
| Total acute hospital length of stay (days), median (IQR): |
|||
| Hospital survivor |
39 (22–66) |
17 (8–28) |
34 (16–75) |
| Hospital non-survivor |
9 (3–29) |
6 (3–22) |
15 (7–31) |
|
|
|||
| ICU bed days (% of total bed days) |
13,808 (0.60) |
391 (0.02) |
1,923 (0.08) |
|
|
|||
| Transfer to another ICU, n (%) |
72 (3.7) |
0 (0.0) |
12 (6.0) |
|
|
|||
| ICU mortality, n (%) |
553 (28.7) |
12 (6.3) |
70 (35.2) |
|
|
|||
| Ultimate hospital mortality, n (%) |
757 (41.5) |
24 (13.0) |
90 (46.6) |
|
Values are n (%), mean (SD) or median (IQR), as indicated. *Percentage of admissions with evidence to assess past medical history. APACHE, Acute Physiology And Chronic Health Evaluation; ICNARC, Intensive Care National Audit & Research Centre; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation. | |||
George et al. Critical Care 2008 12(Suppl 1):S1 doi:10.1186/cc6141 |
|||